Table Info

Table 1.

Drugs and biologics that have shown positive results in clinical research to slow or reverse normal aging processes

Family	Indication	Leading agent	Study type	Reference
Longevity candidates	Longevity	Vitamin D	Observational	[34, 36]
Longevity candidates	Longevity	Metformin	Observational	[40]
Mesenchymal stem cells	Locomotion frailty	Lomecel-B	RCT (phase 2)	[47]
Mesenchymal stem cells	Facial rejuvenation	SVF	RCT	[54]
Senolytics drugs	Cognitive decline	D + Q	OL (phase 1)	[58]
Sirtuin activators	Aging frailty	Resveratrol	RCT (phase 2)	[61]
NAD⁺ precursors	Physical performance	NRS	RCT	[65]

SVF: stromal vascular fraction; D + Q: dasatinib and quercetin; NRS: nicotinamide riboside supplements; OL: open-label

Declarations

Author contributions

RPG: Conceptualization, Writing—review & editing.

Conflicts of interest

The author declares that he has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical frailty: ICFSR international clinical practice guidelines for identification and management. J Nutr Health Aging. 2019;23:771–87. [DOI] [PubMed] [PMC]

Laskovs M, Partridge L, Slack C. Molecular inhibition of RAS signalling to target ageing and age-related health. Dis Model Mech. 2022;15:dmm049627. [DOI] [PubMed] [PMC]

Garay RP. Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu. Expert Opin Investig Drugs. 2021;30:749–58. [DOI] [PubMed]

Garay RP. Recent clinical trials with stem cells to slow or reverse normal aging processes. Front Aging. 2023;4:1148926. [DOI] [PubMed] [PMC]

Sun XL, Hao QK, Tang RJ, Xiao C, Ge ML, Dong BR. Frailty and rejuvenation with stem cells: therapeutic opportunities and clinical challenges. Rejuvenation Res. 2019;22:484–97. [DOI] [PubMed] [PMC]

Zhu Y, Ge J, Huang C, Liu H, Jiang H. Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics. Theranostics. 2021;11:5675–85. [DOI] [PubMed] [PMC]

Chaib S, Tchkonia T, Kirkland JL. Cellular senescence and senolytics: the path to the clinic. Nat Med. 2022;28:1556–68. [DOI] [PubMed] [PMC]

Wyles SP, Tchkonia T, Kirkland JL. Targeting cellular senescence for age-related diseases: path to clinical translation. Plast Reconstr Surg. 2022;150. [DOI] [PubMed] [PMC]

Zhang L, Pitcher LE, Prahalad V, Niedernhofer LJ, Robbins PD. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J. 2023;290:1362–83. [DOI] [PubMed]

10.

Dai H, Sinclair DA, Ellis JL, Steegborn C. Sirtuin activators and inhibitors: promises, achievements, and challenges. Pharmacol Ther. 2018;188:140–54. [DOI] [PubMed] [PMC]

11.

Watroba M, Szukiewicz D. Sirtuins at the service of healthy longevity. Front Physiol. 2021;12:724506. [DOI] [PubMed] [PMC]

12.

Toniolo L, Concato M, Giacomello E. Resveratrol, a multitasking molecule that improves skeletal muscle health. Nutrients. 2023;15:3413. [DOI] [PubMed] [PMC]

13.

Wiciński M, Erdmann J, Nowacka A, Kuźmiński O, Michalak K, Janowski K, et al. Natural phytochemicals as SIRT activators—focus on potential biochemical mechanisms. Nutrients. 2023;15:3578. [DOI] [PubMed] [PMC]

14.

Barker FJ, Hart A, Sayer AA, Witham MD. Effects of nicotinamide adenine dinucleotide precursors on measures of physical performance and physical frailty: a systematic review. JCSM Clin Rep. 2022;7:93–106. [DOI]

15.

Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF. Preclinical and clinical evidence of NAD⁺ precursors in health, disease, and ageing. Mech Ageing Dev. 2021;199:111567. [DOI] [PubMed]

16.

Nielsen JL, Bakula D, Scheibye-Knudsen M. Clinical trials targeting aging. Front Aging. 2022;3:820215. [DOI]

17.

Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, et al. NAD⁺ in aging: molecular mechanisms and translational implications. Trends Mol Med. 2017;23:899–916. [DOI] [PubMed] [PMC]

18.

Yoshino J, Baur JA, Imai SI. NAD⁺ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27:513–28. [DOI] [PubMed] [PMC]

19.

Tchkonia T, Palmer AK, Kirkland JL. New horizons: novel approaches to enhance healthspan through targeting cellular senescence and related aging mechanisms. J Clin Endocrinol Metab. 2021;106:e1481–7. [DOI] [PubMed] [PMC]

20.

Moskalev A, Guvatova Z, Lopes IA, Beckett CW, Kennedy BK, De Magalhaes JP, et al. Targeting aging mechanisms: pharmacological perspectives. Trends Endocrinol Metab. 2022;33:266–80. [DOI] [PubMed]

21.

Fraser HC, Kuan V, Johnen R, Zwierzyna M, Hingorani AD, Beyer A, et al. Biological mechanisms of aging predict age-related disease co-occurrence in patients. Aging Cell. 2022;21:e13524. [DOI] [PubMed] [PMC]

22.

ITP [Internet]. [cited 2023 Jul 28]. Available from: https://www.nia.nih.gov/research/dab/interventions-testing-program-itp

23.

Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–5. [DOI]

24.

Harrison DE, Strong R, Allison DB, Ames BN, Astle CM, Atamna H, et al. Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2014;13:273–82. [DOI] [PubMed] [PMC]

25.

Huggins B, Farris M. Vitamin D₃ promotes longevity in Caenorhabditis elegans. Geroscience. 2023;45:345–58. [DOI]

26.

Ehninger D, Neff F, Xie K. Longevity, aging and rapamycin. Cell Mol Life Sci. 2014;71:4325–46. [DOI] [PubMed] [PMC]

27.

DiNicolantonio JJ, Bhutani J, O’Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart. 2015;2:e000327. [DOI] [PubMed] [PMC]

28.

Lin YC, Chen YC, Hsiao HP, Kuo CH, Chen BH, Chen YT, et al. The effects of acarbose on chemokine and cytokine production in human monocytic THP-1 cells. Hormones (Athens). 2019;18:179–87. [DOI] [PubMed]

29.

Sadagurski M, Cady G, Miller RA. Anti-aging drugs reduce hypothalamic inflammation in a sex-specific manner. Aging Cell. 2017;16:652–60. [DOI] [PubMed] [PMC]

30.

Cheng FF, Liu YL, Du J, Lin JT. Metformin’s mechanisms in attenuating hallmarks of aging and age-related disease. Aging Dis. 2022;13:970–86. [DOI] [PubMed] [PMC]

31.

Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010;20:1352–60. [DOI] [PubMed] [PMC]

32.

Luxwolda MF, Kuipers RS, Kema IP, Dijck-Brouwer DA, Muskiet FA. Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. Br J Nutr. 2012;108:1557–61. [DOI] [PubMed]

33.

Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, Tmava Berisha A, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020;74:1498–513. [DOI] [PubMed] [PMC]

34.

Zeng J, Li T, Sun B, Miao X, Wang L, Ma LC, et al. Change of vitamin D status and all-cause mortality among Chinese older adults: a population-based cohort study. BMC Geriatr. 2022;22:245. [DOI] [PubMed] [PMC]

35.

Chinese longitudinal healthy longevity survey (CLHLS), 1998-2014 [Internet]. The Regents of the University of Michigan; c2024 [cited 2023 Aug 2]. Available from: https://doi.org/10.3886/ICPSR36692.v1

36.

Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. Lancet Diabetes Endocrinol. 2024;12:e2–11. [DOI] [PubMed] [PMC]

37.

Kulkarni AS, Brutsaert EF, Anghel V, Zhang K, Bloomgarden N, Pollak M, et al. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell. 2018;17:e12723. [DOI] [PubMed] [PMC]

38.

Tacutu R, Craig T, Budovsky A, Wuttke D, Lehmann G, Taranukha D, et al. Human ageing genomic resources: integrated databases and tools for the biology and genetics of ageing. Nucleic Acids Res. 2013;41:D1027–33. [DOI] [PubMed] [PMC]

39.

Luo S, Wong ICK, Chui CSL, Zheng J, Huang Y, Schooling CM, et al. Effects of putative metformin targets on phenotypic age and leukocyte telomere length: a mendelian randomisation study using data from the UK Biobank. Lancet Healthy Longev. 2023;4:e337–44. [DOI] [PubMed]

40.

Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev. 2017;40:31–44. [DOI] [PubMed]

41.

Overview on the regulation of cellular therapies in aesthetic medicine [Internet]. [cited 2023 Aug 2]. Available from: https://www.aslms.org/docs/default-source/for-professionals/resources/task-force-whitepaper-2019-final-4-9-21.pdf

42.

Padki MM, Stambler I. Targeting aging with metformin (TAME). In: Gu D, Dupre ME, editors. Encyclopedia of gerontology and population aging. Cham: Springer International Publishing; 2021. pp. 4908–10.

43.

Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23:1060–5. [DOI] [PubMed] [PMC]

44.

Glossmann HH, Lutz OMD. Metformin and aging: a review. Gerontology. 2019;65:581–90. [DOI] [PubMed]

45.

Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011;27:1–15. [DOI] [PubMed] [PMC]

46.

Golpanian S, DiFede DL, Khan A, Schulman IH, Landin AM, Tompkins BA, et al. Allogeneic human mesenchymal stem cell infusions for aging frailty. J Gerontol A Biol Sci Med Sci. 2017;72:1505–12. [DOI] [PubMed] [PMC]

47.

Tompkins BA, DiFede DL, Khan A, Landin AM, Schulman IH, Pujol MV, et al. Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, double-blind, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci. 2017;72:1513–22. [DOI] [PubMed] [PMC]

48.

Larrick JW, Mendelsohn AR. Mesenchymal stem cells for frailty? Rejuvenation Res. 2017;20:525–9. [DOI] [PubMed]

49.

Ocansey DKW, Pei B, Yan Y, Qian H, Zhang X, Xu W, et al. Improved therapeutics of modified mesenchymal stem cells: an update. J Transl Med. 2020;18:42. [DOI] [PubMed] [PMC]

50.

Salvadori M, Cesari N, Murgia A, Puccini P, Riccardi B, Dominici M. Dissecting the pharmacodynamics and pharmacokinetics of mscs to overcome limitations in their clinical translation. Mol Ther Methods Clin Dev. 2019;14:1–15. [DOI] [PubMed] [PMC]

51.

Kadri N, Amu S, Iacobaeus E, Boberg E, Le Blanc K. Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cell Mol Immunol. 2023;20:613–25. [DOI] [PubMed] [PMC]

52.

Coleman SR. The technique of periorbital lipoinfiltration. Oper Tech Plast Reconstr Surg. 1994;1:120–6. [DOI]

53.

Surowiecka A, Strużyna J. Adipose-derived stem cells for facial rejuvenation. J Pers Med. 2022;12:117. [DOI] [PubMed] [PMC]

54.

Yin Y, Li J, Li Q, Zhang A, Jin P. Autologous fat graft assisted by stromal vascular fraction improves facial skin quality: a randomized controlled trial. J Plast Reconstr Aesthet Surg. 2020;73:1166–73. [DOI] [PubMed]

55.

Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. Clearance of p16^Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479:232–6. [DOI] [PubMed] [PMC]

56.

Zhu Y, Tchkonia T, Pirtskhalava T, Gower AC, Ding H, Giorgadze N, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14:644–58. [DOI] [PubMed] [PMC]

57.

Zhu Y, Doornebal EJ, Pirtskhalava T, Giorgadze N, Wentworth M, Fuhrmann-Stroissnigg H, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-X_L inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017;9:955–63. [DOI] [PubMed] [PMC]

58.

Gonzales MM, Garbarino VR, Kautz TF, Palavicini JP, Lopez-Cruzan M, Dehkordi SK, et al. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial. Nat Med. 2023;29:2481–8. [DOI] [PubMed] [PMC]

59.

Orr M, Gonzales M, Garbarino V, Kautz T, Palavicini J, Lopez-Cruzan M, et al. Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – outcomes from the first clinical trial of senolytic therapy for Alzheimer’s disease. [Preprint]. 2023 [cited 2023 Aug 2]. Available from: https://www.researchsquare.com/article/rs-2809973/v1

60.

Barrera-Vázquez OS, Magos-Guerrero GA, Escobar-Ramírez JL, Gomez-Verjan JC. Natural products as a major source of candidates for potential senolytic compounds obtained by in silico screening. Med Chem. 2023;19:653–68. [DOI] [PubMed]

61.

Harper SA, Bassler JR, Peramsetty S, Yang Y, Roberts LM, Drummer D, et al. Resveratrol and exercise combined to treat functional limitations in late life: a pilot randomized controlled trial. Exp Gerontol. 2021;143:111111. [DOI] [PubMed] [PMC]

62.

Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, et al. The NAD⁺/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154:430–41. [DOI] [PubMed] [PMC]

63.

Zhu XH, Lu M, Lee BY, Ugurbil K, Chen W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A. 2015;112:2876–81. [DOI] [PubMed] [PMC]

64.

Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD⁺ metabolism in human tissue. PLoS One. 2012;7:e42357. [DOI] [PubMed] [PMC]

65.

Dolopikou CF, Kourtzidis IA, Margaritelis NV, Vrabas IS, Koidou I, Kyparos A, et al. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study. Eur J Nutr. 2020;59:505–15. [DOI] [PubMed]

66.

Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. [DOI] [PubMed] [PMC]